Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Foon

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Blood|March 31, 2012
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemiaKenneth A Foon, Dhaval Mehta, Suzanne Lentzsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemiaMiroslaw J Szczepanski, Marta Szajnik, Malgorzata Czystowska, et al.
Leukemia Research|February 15, 2011
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapyDhaval R Mehta, Kenneth A Foon, Robert L Redner, et al.
Cancer Immunology, Immunotherapy : CII|July 27, 2005
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic miceAsim Saha, Rathindra Nath Baral, Sunil K Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaKenneth A Foon, Michael Boyiadzis, Stephanie R Land, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphomaSamuel A Jacobs, Steven H Swerdlow, Jeffrey Kant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2004
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerEric K Rowinsky, Garry H Schwartz, Jared A Gollob, et al.
Blood|January 5, 2006
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLLAnthony G Brickner, Anne M Evans, Jeffrey K Mito, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon, Xiao-Dong Yang, Louis M Weiner, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Blood|March 31, 2012
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemiaKenneth A Foon, Dhaval Mehta, Suzanne Lentzsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemiaMiroslaw J Szczepanski, Marta Szajnik, Malgorzata Czystowska, et al.
Leukemia Research|February 15, 2011
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapyDhaval R Mehta, Kenneth A Foon, Robert L Redner, et al.
Cancer Immunology, Immunotherapy : CII|July 27, 2005
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic miceAsim Saha, Rathindra Nath Baral, Sunil K Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaKenneth A Foon, Michael Boyiadzis, Stephanie R Land, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphomaSamuel A Jacobs, Steven H Swerdlow, Jeffrey Kant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2004
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerEric K Rowinsky, Garry H Schwartz, Jared A Gollob, et al.
Blood|January 5, 2006
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLLAnthony G Brickner, Anne M Evans, Jeffrey K Mito, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon, Xiao-Dong Yang, Louis M Weiner, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Pageof 5